Clinical trial

Close up of vaccine syringe
#Biopharma #Clinical trial #Tourette

First patient dosed with new Tourette syndrome therapy 

The first patient has been dosed in a trial for an investigational Tourette syndrome therapy.  Biopharmaceutical company Emalex Biosciences announced that the first patient was dosed in its expanded access programme for ecopipam, an investigational first-in-class D1 receptor antagonist in development for the treatment of Tourette syndrome.  … Read More

#News

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

Baby on a respirator - RSV
#Clinical trial #Immunology / Virology & Vaccines #Respiratory syncytial virus

International study will investigate RSV prevention in infants

A new international clinical trial has been launched to compare existing prevention options to protect babies from respiratory syncytial virus (RSV).  The PIPELINE-RSV trial, sponsored by Penta, will evaluate two licensed RSV prevention tools. The RSV vaccine which is routinely offered to all pregnant individuals in the… Read More

#News

The European Medicines Agency building
#CHMP #Clinical trial #European Medicines Agency

CHMP issues positive opinion on CSU targeted therapy 

The European Medicines Agency (EMA)’s Committee for Medicinal Products (CHMP) has adopted a positive opinion recommending marketing authorisation for a chronic spontaneous urticaria (CSU) treatment.  The opinion means remibrutinib, a highly selective oral BTKi developed by Novartis, could be the first targeted therapy approved for CSU in Europe.  The positive CHMP opinion is supported… Read More

#News #Regulatory

#Clinical trial #Drug discovery #ischaemic stroke #Proteins

How DiaMedica aims to reshape treatments for ischemic diseases

DDW Editor Reece Armstrong speaks to Rick Pauls, CEO of DiaMedica, about the company’s efforts in ischemic diseases and the challenges of drug discovery in this field.   RA: How did DiaMedica decide to explore the therapy area of ischemia?   RP: Ischemic diseases driven by restricted blood flow and endothelial dysfunction, such as preeclampsia (PE), fetal growth restriction (FGR), and… Read More

#Exclusive Content

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Prostate cancer #UK #ViiV Healthcare

DDW Highlights: 3 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More

#Podcasts

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

#Clinical trial #Liverpool School of Tropical Medicine

Ophirex to produce snake venom inhibitor for LSTM study 

Public benefit corporation Ophirex has entered an agreement to produce a snake venom inhibitor for the Liverpool School of Tropical Medicine (LSTM).  Marimastat is an inhibitor of snake venom metalloproteinases, a major snake venom toxin which plays a primary role in the digestion of tissues, leading to swelling, necrosis and internal… Read More

#News

Woman standing on scales
#Biopharmaceutical #Clinical trial #GLP-1 #Weight loss

Verdiva Bio completes enrolment for oral GLP-1 trial 

Biopharmaceutical company Verdiva Bio has completed its participant enrolment for the Phase IIb study of its once-weekly oral GLP-1.  VRB-101 is a once-weekly oral, cAMP-biased, GLP-1 peptide analogue candidate for body weight reduction in people with overweight or obesity.  The Phase IIb EVOLVE-2 trial is randomised, double-blind… Read More

#News

#Cell and gene therapy #Clinical trial #CRO

De-risking cell & gene therapy development with advanced analytical testing

Amy Glekas, Head of Field Development and Interim Head of Sales at Solvias, explores the opportunities that analytical testing can offer cell and gene therapy developers.  Cell and gene therapies (CGTs) have commanded public attention for decades. There are the big milestones, for example, the major gene therapy approvals, a decade of CAR T-induced cancer remission and the first patient-specific, in vivo gene editing treatment. However, in a more guarded investment climate, obstacles like adverse events and… Read More

#Exclusive Content

Stem cell transplant
#Biologics License Application (BLA) #Clinical trial #FDA

FDA accepts BLA for kidney transplant drug imlifidase

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for a drug desensitising highly sensitised adult kidney transplant patients.  Imlifidase, developed by biopharmaceutical company Hansa Pharma, is a unique IgG cleaving enzyme that rapidly inactivates over 95% of donor-specific antibodies within two to six hours of administration, providing a crucial… Read More

#News #Regulatory

Medical laboratory
#ABPI #Clinical trial #UK

Boost in trial activity would have huge gains, report says 

A new report has highlighted the health and economic opportunity from boosting industry clinical trials.  A report from the European Federation of Pharmaceutical Industries and Associations (EFPIA) highlights increasing clinical trial activity across Europe would have significant health, economic and productivity returns.  According to… Read More

#News

#Clinical trial #Drug discovery #Milner Therapeutics Institute #UK

The role of universities and industry in driving translation of therapeutics

Professor Cathy Tralau-Stewart PhD, Executive Director, Milner Therapeutics Institute, University of Cambridge, UK, asks why a new approach is needed in the UK for getting therapies to the market. Evolution of the translational path   Academic institutions contribute a substantial share of the therapeutic approaches that ultimately reach patients (1), but the path to translating such innovation to… Read More

#Exclusive Content

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

DDW Highlights: 24 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers found an unexpected drug could help treat depression. Elsewhere, a new company is… Read More

#Podcasts

Clostridioides difficile
#Bacteria #Clinical trial #National Institute for Health and Care Research

UK study tests new preventative therapy for C. difficile

A study investigating a life-threatening and contagious gut infection has launched in the UK – with researchers recruiting the first patient in the world to test a new preventative therapy.  Clostridioides difficile, commonly known as C. difficile or ‘C. diff’, is a bacterium that lives in the… Read More

#News

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

This week in Drug Discovery (16 – 20 February) 

News round-up for 16 – 20 February by Bruno Quinney, Content Team at DDW.  This week in DDW, an unexpected drug could help treat depression. Elsewhere, a new company is set to advance a cerebral palsy therapy.  The top stories:    Psychedelic drug could help treat depression … Read More

#News